![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Retinal vein occlusion (RVO) is currently the second cause of visual impairment due to retinal disease just after diabetic retinopathy. Branch retinal vein occlusions (BRVO) are complicated by macular edema (ME) in up to 98% of cases. ME is the major cause of BRVO-related visual acuity impairment. The diffusion of intravitreal drugs, like VEGF inhibitors (anti-VEGF) or implantable steroids, have dramatically changed the ME management and its prognosis. Therefore, we aim to summarize and review the main clinical and therapeutic aspects of this condition.
Financial & competing interests disclosure
F Bandello is an advisory board member for Allergan, Novartis Pharmaceuticals Corp., Farmila-Thea, Bayer Schering Pharma, Pfizer, Alcon, Bausch and Lomb, Genentech, Alimera Sciences, Sanofi Aventis, Thrombogenics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Key issues
• Branch retinal vein occlusion (BRVO) is currently the second cause of visual impairment due to retinal disease just after diabetic retinopathy.
• Currently anti-VEGF drugs and steroid implant devices are the milestones of macular edema (ME) due to BRVO management.
• Future perspectives include new treatment algorithms addressing each BRVO sub-type with a different and specific treatment.